Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
[Delayed]Presentation Material for Business Plan and Growth Potential
StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock
StemRIM Announces Patent Registration for Stem Cell Gene Therapy Technology (Development Code SR-GT1) Aimed at Curative Treatment of Dystrophic Epider
StemRIM Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Psorias
StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator
StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company's Executive Officers, Employees, and External Collaborators
Presentation Material Financial Results for the Fiscal Year Ended July31,2025
StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees
StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors
Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2025 [Japanese GAAP]
StemRIM Announces Progress of the Additional Phase 2 Clinical Trial on Redasemtide (HMGB1 Fragment Peptide) for Dystrophic Epidermolysis Bullosa
StemRIM Announces Publication of a Paper on Redasemtide (HMGB1 Fragment Peptide) for Liver Cirrhosis
Non-consolidated Financial Results for the Nine Months Ended April 30, 2025 [Japanese GAAP]
StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide, Redasemtide
StemRIM Announces Setting the Record Date and Holding for Extraordinary General Meeting of Shareholders and Reduction of Capital Stock
StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide
StemRIM Announces the Interim Analysis Results for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke